Review: GLP-1 Receptor Agonists Show Promise for Improving Ovarian Function in PCOS and Obesity

Many women face challenges with polycystic ovary syndrome (PCOS) and obesity-related reproductive dysfunction, conditions characterized by hormonal imbalances, insulin resistance, and impaired fertility. Current treatments often address symptoms but lack comprehensive solutions for restoring ovarian function. Incretin-based therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have emerged as potential agents due to their established benefits in metabolic health, raising interest in their impact on reproductive endocrinology and fertility.

This comprehensive scientific literature review synthesized evidence from 30 highly relevant studies to examine the mechanisms, clinical outcomes, and safety profile of incretin therapies on ovarian function. The review systematically analyzed data from various study types, including randomized controlled trials, meta-analyses, animal models, and in vitro studies, focusing on their relevance to PCOS and obesity-related reproductive issues. The authors aimed to provide a balanced synthesis of current knowledge and identify critical gaps in the literature.

Evidence suggests GLP-1 RAs exert beneficial effects through multiple molecular pathways, including FOXO1 signaling, modulation of steroidogenesis, and enhancement of insulin sensitivity. Most mechanistic data, however, derive from animal models and in vitro studies, lacking validation in human ovarian tissue. Clinical outcomes from randomized controlled trials and meta-analyses consistently show improvements in menstrual regularity, hormonal profiles, and spontaneous conception rates. > While preliminary safety data regarding inadvertent early pregnancy exposure are reassuring, animal studies suggest potential dose-dependent risks that warrant careful consideration. However, the certainty of this clinical evidence is limited by small sample sizes, short study durations, high heterogeneity among studies, and restriction to overweight/obese populations.